STOCK TITAN

Pliant Therapeutics Inc - PLRX STOCK NEWS

Welcome to our dedicated news page for Pliant Therapeutics (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pliant Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pliant Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
management
Pliant Therapeutics Inc

Nasdaq:PLRX

PLRX Rankings

PLRX Stock Data

852.38M
47.09M
6.63%
111.28%
12.39%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
South San Francisco

About PLRX

pliant therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. by harnessing the therapeutic potential of integrin biology and tgf-β modulation, pliant aims to prevent or even reverse fibrosis to address the needs of many patients. the company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. pliant’s co-founders include world-renowned researchers from university of california, san francisco (ucsf), who bring broad experience in fibrosis biology and small molecule chemistry. together, the pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.